News

December 21, 2020December 21, 2020

NexImmune, City of Hope Partner to Research NEXI-001, New Therapies

News

NexImmune and City of Hope have teamed up on a research initiative aimed at advancing treatment candidate NEXI-001 for acute myeloid leukemia (AML) and identifying new targets for future ... Read more

December 17, 2020December 17, 2020

Venclexta Combos Approved in Canada to Treat Newly Diagnosed AML

News

Health Canada has approved Venclexta (venetoclax) in combination with Vidaza (azacitidine) or low-dose cytarabine to treat newly diagnosed adults, ages 75 and older, with acute myeloid leukemia (AML), who have ... Read more

December 14, 2020December 17, 2020

Potential Cancer Vaccine DCP-001 May Control AML Residual Disease

News

DCP-001, the lead cancer vaccine candidate by DCprime, safely elicited a tumor-specific immune response in patients with acute myeloid leukemia (AML), who still showed signs of residual disease despite ... Read more

December 10, 2020December 10, 2020

OSU Names Leukemia Research Center in Honor of Scientist Clara Bloomfield

News

Clara D. Bloomfield dedicated her career to finding new treatments for patients with acute myeloid leukemia (AML) and related disorders. To continue the work of its longtime faculty member, Ohio ... Read more

December 7, 2020December 7, 2020

First-in-Human Trial Testing NKX101 Natural Killer Cell Therapy Treats First Patient

News

The first patient has received treatment in a first-in-human Phase 1 trial of NKX101, Nkarta‘s investigational cell therapy for the treatment of relapsed/refractory acute myeloid leukemia (AML) or higher-risk ... Read more

December 2, 2020December 3, 2020

FDA Puts Eprenetapopt on Fast Track for Treating TP53 Mutant AML

News

Eprenetapopt (APR-246), an investigational therapy being developed by Aprea Therapeutics, has been granted fast track designation by the U.S. Food and Drug Administration for treating acute myeloid leukemia (AML) with mutations in the TP53 ... Read more

November 30, 2020November 30, 2020

NORD Push for Rare Disease Advisory Councils Focus of Dec. 16 Public Meeting

News, syndicated

To empower and equip members of the rare disease community to engage state leaders in matters of importance to patients and their families, the National Organization for Rare Disorders ... Read more

November 19, 2020November 19, 2020

Dana-Farber Scientist Awarded $400K to Seek New Therapies for Childhood AML

News

Kimberly Stegmaier, MD, of the Dana-Farber Cancer Institute, has been awarded a $400,000 research grant to continue her work to find new treatments for pediatric acute myeloid leukemia (AML) ... Read more

November 16, 2020November 16, 2020

US Trial Testing Mylotarg Plus Venclexta for AML Now Enrolling Participants

News

A Phase 1b study testing Mylotarg (gemtuzumab ozogamicin) plus Venclexta (venetoclax) for adults with relapsing or refractory acute myeloid leukemia (AML) is currently enrolling patients. The trial (NCT04070768) is taking place across four clinical ... Read more

November 12, 2020November 12, 2020

FDA Grants Orphan Drug Designation to Immune-Onc’s IO-202

News

The U.S. Food and Drug Administration (FDA) has given the designation of orphan drug to Immune-Onc Therapeutics’ investigational antibody-based therapy IO-202 for the treatment of acute myeloid leukemia (AML). ... Read more